Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Fewer seizures, better behavior seen with STK-001 treatment for Dravet

STK-001, an investigational treatment for children and adolescents with Dravet syndrome, markedly reduced seizure frequency and improved cognition and behavior, according to new findings in Phase 1/2a clinical trials. “The substantial and sustained reductions in seizure frequency and improvements in cognition and behavior observed in our STK-001 clinical studies…

DEA lifts Fintepla’s Schedule IV controlled substance status

Note: This article was updated April 21, 2023, to reflect that Fintepla was originally classified a Schedule IV controlled substance due to its low risk of abuse or misuse. A risk evaluation and mitigation strategy established by Zogenix that limits Fintepla’s access due to links with cardiovascular-related side effects remains…

Stoke’s Phase 3 Trial of STK-001 for Dravet Planned for Next Year

New safety and efficacy data from two Phase 1/2a clinical trials testing STK-001, Stoke Therapeutics’ investigational treatment for children and adolescents with Dravet syndrome, are expected as early as mid-year. Interim results from the ongoing Phase 1/2a MONARCH (NCT04442295) and ADMIRAL (ISRCTN99651026) trials, reported late last…

Expert Panel Reaches Consensus in Dravet Diagnosis, Management

An international panel of physicians and caregivers with expertise in Dravet syndrome is recommending genetic testing in children ages 2 to 15 months who develop normally but have a prolonged seizure after fever or vaccination. Among several consensus statements, the panel also recommended a number of currently available therapies…